Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Cancer Discov. 2020 Jun 22;10(9):1352–1373. doi: 10.1158/2159-8290.CD-19-1228

Figure 3: Aggressive TNBC brain metastases are serine prototrophs.

Figure 3:

(A) Fractional labeling of intracellular U-13C-glucose-derived m+3 serine from aggressive or indolent brain metastatic cells grown in Plasma, CSF, or -Ser/-Gly media.

(B) Proliferative capacity of aggressive or indolent TNBC BrM cells grown in Plasma, CSF, or -Ser/-Gly media.

(C) Fractional labeling of intracellular U-13C-glucose-derived serine from aggressive brain-trophic cell lines expressing a control shRNA (shCtrl) or PHGDH shRNA (shPHGDH #1 or shPHGDH #2)

(D) Proliferative capacity of aggressive TNBC BrM cells expressing a control shRNA (shCtrl) or PHGDH shRNA (shPHGDH #1 or shPHGDH #2).

(E) Fractional labeling of intracellular U-13C-glucose -derived serine in aggressive TNBC BrM cells with a PHGDH shRNA (shPHGDH #2) expressing either an empty vector (EV) control, catalytically active or catalytically inactive, shRNA-resistant PHGDH.

(F) Proliferative capacity of PHGDH knockdown aggressive TNBC BrM cells with a PHGDH shRNA (shPHGDH #2) expressing either an empty vector (EV) control, catalytically active or catalytically inactive, shRNA-resistant PHGDH.

Cell proliferation data was monitored over 4-6 days using an Incucyte or Multisizer Coulter Counter. Error bars represent standard deviations.